Stock Focus on CTI BioPharma Corp. (NASDAQ:CTIC)

CTI BioPharma Corp. (NASDAQ:CTIC) shares have moved +0.2960% in the most recent trading session. In the session, the stock touched a high of $0.4066 and saw a low of $0.4000. Shares have been recently noted at +3.8127% away from the 50 day moving average of $0.3917. Tracking the stock price relative to its moving averages may be usefull when trying to gauge future share movement. If shares are trading above the moving average, the moving average may give a support level. If the shares are trading below a moving average, the average may offer a resistance level. 

Taking a longer term look at where the stock has been and where it’s headed, we note that currently the stock has traded in the range of $0.2514 – 1.3400 over the past 52-weeks. The latest bid places it $-0.9334 away from the 52-week high of $1.3400, or -69.6567%. On the other end, the latest bid puts the equity $0.1552 away from the 52-week low of $0.2514, or +61.7343%. The 52-week metric serves as an important parameter for investors as they gauge the current price level of a stock and where it might be headed in the future.

Another important metric used by institutional and retail investors alike, is the analyst price target on a stock. Wall Street brokerage firms on the sell-side hire analysts to conduct research on stocks they cover for their clients. Analysts issue reports which often include a future stock price projection for the stock. Thomson Reuters’ First Call, which many consider to be the benchmark for EPS and consensus data, currently have the price target listed as $0.3800. This is the consensus of all analyst targets from the brokerage firms polled by First Call.

The information provided on this website is for individual use only and should be considered strictly informational in nature. The article is not advice, and should not be treated as such. We are in no way responsible for any investment loss or damages. All content in our articles is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Neither the information presented nor any statement or expression of opinion, or any other matter herein, directly or indirectly constitutes a solicitation of the purchase or sale of any securities.

Viewers should always consult with a licensed securities professional before purchasing or selling any securities of companies profiled or discussed in our articles. It is possible that a viewer’s entire investment may be lost or impaired due to the speculative nature of the companies profiled. We make no recommendation that the securities of the companies profiled or discussed in on our website should be purchased, sold or held by investors. 

COMMENTS